Board of Directors

Michael Altman, CFA
Michael Altman, CFA
Managing Director, Perceptive Advisors

Michael Altman joined Perceptive in 2007 and is a Managing Director on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael served on the board of directors of Vensun Pharmaceuticals from November 2016 to January 2019. He currently serves on the board of directors of Vitruvius Therapeutics.

Edward Anderson
Edward Anderson
Founder, Northbridge Venture Partners

Ed Anderson is the founder of North Bridge Venture Partners and North Bridge Growth Equity. Mr. Anderson holds a B.F.A. from the University of Denver and an M.B.A. from Columbia University Graduate School of Business.

Robert Langer, D.Sc.
Robert Langer, D.Sc.
David H. Koch Institute Professor, Massachusetts Institute of Technology

Robert Langer is currently serving on the respective boards of directors of Abpro Corporation,  Frequency Therapeutics, Inc., Rubius Therapeutics, Inc., Moderna, Inc., and Puretech Health plc.  He received his Bachelor’s Degree from Cornell University and his Sc.D. from the Massachusetts Institute of Technology, both in Chemical Engineering.

Ann Merrifield
Ann Merrifield
Life Sciences Advisor and Board Director

Ann Merrifield currently serves as board director for a portfolio of public and private companies in the life sciences sector which include Flexion Therapeutics, Inc., InVivo Therapeutics Holdings Corp., and Veritas Genetics Inc.

Previously, she spent an 18-year career at Genzyme Corporation, a diversified global biotechnology company. While at Genzyme, Ann served as President, Genzyme Biosurgery, where she led global business strategy and operations across a portfolio of biologics and therapeutic devices. She also served as President, Genzyme Genetics, playing a key role in developing this start-up genetic diagnostics business and bringing it to profitability.

Following Genzyme from 2012-2014, she served as President, Chief Executive Officer and director of PathoGenetix Inc., a genomics company. Ms. Merrifield holds a B.A. in Zoology and a Master of Education from the University of Maine and an M.B.A. from the Tuck School of Business at Dartmouth College.

Maria Palasis, Ph.D.
Maria Palasis, Ph.D.
President and Chief Executive Officer

Maria Palasis has served as Lyra’s President and Chief Executive Officer and a member of its board of directors since January 2015. Previously, Dr. Palasis held positions of increasing responsibility, the most recent of which was Executive Vice President and Chief Technology Officer from 2011 to 2015. Before that, in 2008, Dr. Palasis joined Arsenal Medical, Inc., a biotechnology company, as Executive Vice President and subsequently served as President and Chief Executive Officer, and a member of the board of directors of Arsenal Medical from January 2015 to June 2018. Prior to that, Dr. Palasis served as Director at Boston Scientific Corporation, a medical device company, where she managed a portfolio of external biotech and medical device investments and led the development of several combination therapies. Dr. Palasis holds a B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

Konstantin Poukalov
Konstantin Poukalov
Managing Director, Perceptive Advisors

Konstantin is a Managing Director at Perceptive Advisors. Mr. Poukalov has also served on the board of directors of Landos Biopharma, Inc., a biopharmaceutical company since August 2019. Previously, Konstantin served as Executive Vice President, Chief Financial Officer of Kadmon from 2014 to 2018. Konstantin earned Bachelor of Engineering, in Electrical Engineering, from Stony Brook University.

Bradford Smith
Bradford Smith
Chief Financial Officer, Treasurer, and Secretary of Homology Medicines

Mr. Smith is currently the Chief Financial Officer of Homology Medicines, Inc. (NASDAQ: FIXX), which he joined in 2017. Prior to joining Homology, he served as Chief Financial Officer of Ocular Therapeutix, Inc., (NASDAQ: OCUL) where he led the company’s strategic financings, including an IPO and subsequent follow-on offerings, and completed a development and commercialization deal with a major biopharmaceutical company. Previously, Mr. Smith has also served as Chief Financial Officer of OmniGuide Inc,. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School at the University of New Hampshire.

George Whitesides, Ph.D.
George Whitesides, Ph.D.
Woodford L. and Ann A. Flowers University Professor, Harvard University

Dr. Whitesides joined Harvard’s department of chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has served on the board of directors of Theravance Biopharma, Inc. since 2013. He is also a co-founder of a number of companies including Genzyme Corporation, GelTex Pharmaceuticals Inc., Theravance Biopharma, Inc., and Arsenal Medical, Inc. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.

Back to Top